Investigating biomarkers in patients with trigeminal neuralgia
Inflammatory Cytokine and Neuropeptide Study in Patients With Trigeminal Neuralgia
This study is testing if certain markers in the blood can help us understand trigeminal neuralgia better and improve pain treatments for people who suffer from this severe facial pain.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 20 Years to 80 Years |
| Sex | All |
| Sponsor | Keimyung University Dongsan Medical Center Academic / other |
| Locations | 1 site (Daegu) |
| Trial ID | NCT05685797 on ClinicalTrials.gov |
What this trial studies
This study aims to explore the expression levels of inflammatory cytokines and neurotransmitters in the blood of patients suffering from primary trigeminal neuralgia (TN). The research focuses on understanding the pathophysiological mechanisms behind TN, which is characterized by severe facial pain. By analyzing biomarkers such as calcitonin gene-related peptide (CGRP), substance P (SP), vasoactive intestinal peptide (VIP), and β-endorphin, the study seeks to provide insights into the effectiveness of treatments like radiofrequency thermocoagulation (RFT) for patients who do not respond well to medication. The ultimate goal is to improve pain management strategies for TN patients.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with trigeminal neuralgia who have a pain rating of more than 4 on the Numeric Rating Scale and have failed medical treatment.
Not a fit: Patients who have allergic reactions to local anesthetics or coagulation abnormalities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better-targeted treatments for patients with trigeminal neuralgia, particularly those who do not respond to conventional medications.
How similar studies have performed: While there have been studies exploring biomarkers in trigeminal neuralgia, this specific approach focusing on inflammatory cytokines and neurotransmitters in blood is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * TN patients with NRS more than 4 * TN patients who failed medical treatment * TN patients showing severe adverse reaction with medication Exclusion Criteria: * Patients showing allergic reaction to local anesthetics * Patients with coagulation abnormality
Where this trial is running
Daegu
- Hong ji HEE — Daegu, Korea, Republic of (Recruiting)
Study contacts
- Study coordinator: Ji H Hong
- Email: swon13@daum.net
- Phone: 01046794343
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.